Home
About
FAQ
History (5)
A phase 1 trial of E7974 administered on day 1 of a 21-day cycle in patients with advanced solid tumors.
Bacterial defenses against oxidants: mechanistic features of cysteine-based peroxidases and their flavoprotein reductases.
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
The catalytic mechanism of peroxiredoxins.
Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The catalytic mechanism of peroxiredoxins.
Poole LB. The catalytic mechanism of peroxiredoxins. Subcell Biochem. 2007; 44:61-81.
View in:
PubMed
subject areas
Antioxidants
Binding Sites
Catalysis
Cysteine
Oxidation-Reduction
Peroxiredoxins
Protein Folding
Protein Structure, Quaternary
Protein Structure, Secondary
authors with profiles
Leslie B. Poole PhD